Shots: The EC’s approval is based on P-III CADMUS Jr study assessing Stelara (SC) in 44 pediatric patients with mod. to sev. PsO aged 6–11 yrs. from 9 countries. The […]readmore
Tags : Moderate-to-Severe Plaque Psoriasis
Shots: The P-IV IXORA-R study involves assessing of Taltz vs Tremfya (guselkumab) in 1,027 patients with moderate to severe plaque psoriasis for a total of 24 wks., with the primary […]readmore
Shots: TGA approval is based on P-III reSURFACE data (N=1862) i.e. (reSURFACE 1 and reSURFACE 2) assessing Ilumya 100mg vs PBO or etanercept, showing PASI 75 reduction in psoriasis severity […]readmore